• Something wrong with this record ?

Oximes as pretreatment before acute exposure to paraoxon

DE. Lorke, SM. Nurulain, MY. Hasan, K. Kuča, GA. Petroianu,

. 2019 ; 39 (11) : 1506-1515. [pub] 20190702

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20028769

Grant support
Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Science - International

Organophosphates, useful agents as pesticides, also represent a serious danger due to their high acute toxicity. There is indication that oximes, when administered before organophosphate exposure, can protect from these toxic effects. We have tested at equitoxic dosage (25% of LD01 ) the prophylactic efficacy of five experimental (K-48, K-53, K-74, K-75, K-203) and two established oximes (pralidoxime and obidoxime) to protect from mortality induced by the organophosphate paraoxon. Mortalities were quantified by Cox analysis and compared with those observed after pretreatment with a strong acetylcholinesterase inhibitor (10-methylacridine) and after the FDA-approved pretreatment compound pyridostigmine. All nine tested substances statistically significantly reduced paraoxon-induced mortality. Best protection was conferred by the experimental oxime K-48, reducing the relative risk of death (RR) to 0.10, which was statistically significantly superior to pyridostigmine (RR = 0.31). The other oximes reduced the RR to 0.13 (obidoxime), 0.20 (K-203), 0.21 (K-74), 0.24 (K-75) and 0.26 (pralidoxime), which were significantly more efficacious than 10-methylacridine (RR = 0.65). These data support the hypothesis that protective efficacy is not primarily due to cholinesterase inhibition and indicate that the tested experimental oximes may be considered promising alternatives to the established pretreatment compound pyridostigmine.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028769
003      
CZ-PrNML
005      
20210114155132.0
007      
ta
008      
210105s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jat.3835 $2 doi
035    __
$a (PubMed)31264735
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Lorke, Dietrich E $u Department of Cellular Biology & Pharmacology, Herbert Wertheim College of Medicine, University Park GL 495 D, Florida International University, Miami, Florida. College of Medicine and Health Sciences, Department of Anatomy and Cellular Biology, Khalifa University, Abu Dhabi, United Arab Emirates.
245    10
$a Oximes as pretreatment before acute exposure to paraoxon / $c DE. Lorke, SM. Nurulain, MY. Hasan, K. Kuča, GA. Petroianu,
520    9_
$a Organophosphates, useful agents as pesticides, also represent a serious danger due to their high acute toxicity. There is indication that oximes, when administered before organophosphate exposure, can protect from these toxic effects. We have tested at equitoxic dosage (25% of LD01 ) the prophylactic efficacy of five experimental (K-48, K-53, K-74, K-75, K-203) and two established oximes (pralidoxime and obidoxime) to protect from mortality induced by the organophosphate paraoxon. Mortalities were quantified by Cox analysis and compared with those observed after pretreatment with a strong acetylcholinesterase inhibitor (10-methylacridine) and after the FDA-approved pretreatment compound pyridostigmine. All nine tested substances statistically significantly reduced paraoxon-induced mortality. Best protection was conferred by the experimental oxime K-48, reducing the relative risk of death (RR) to 0.10, which was statistically significantly superior to pyridostigmine (RR = 0.31). The other oximes reduced the RR to 0.13 (obidoxime), 0.20 (K-203), 0.21 (K-74), 0.24 (K-75) and 0.26 (pralidoxime), which were significantly more efficacious than 10-methylacridine (RR = 0.65). These data support the hypothesis that protective efficacy is not primarily due to cholinesterase inhibition and indicate that the tested experimental oximes may be considered promising alternatives to the established pretreatment compound pyridostigmine.
650    _2
$a zvířata $7 D000818
650    _2
$a reaktivátory cholinesterasy $x aplikace a dávkování $x farmakologie $7 D002801
650    _2
$a LD50 $7 D007928
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a obidoxim chlorid $x aplikace a dávkování $x farmakologie $7 D009768
650    _2
$a paraoxon $x chemie $x toxicita $7 D010261
650    _2
$a pralidoximové sloučeniny $x aplikace a dávkování $x farmakologie $7 D011220
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a ochranné látky $x aplikace a dávkování $x farmakologie $7 D020011
650    _2
$a potkani Wistar $7 D017208
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nurulain, Syed M $u Department of Bio Science, COMSATS Institute of Information Technology, Islamabad, Pakistan.
700    1_
$a Hasan, Mohamed Y $u Department of Pharmacology & Therapeutics, College of Medicine and Health Sciences, UAE University, United Arab Emirates.
700    1_
$a Kuča, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Petroianu, Georg A $u Department of Cellular Biology & Pharmacology, Herbert Wertheim College of Medicine, University Park GL 495 D, Florida International University, Miami, Florida.
773    0_
$w MED00008416 $t Journal of applied toxicology : JAT $x 1099-1263 $g Roč. 39, č. 11 (2019), s. 1506-1515
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31264735 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114155130 $b ABA008
999    __
$a ok $b bmc $g 1609104 $s 1119949
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 39 $c 11 $d 1506-1515 $e 20190702 $i 1099-1263 $m JAT. Journal of applied toxicology $n J Appl Toxicol $x MED00008416
GRA    __
$p Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Science $2 International
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Archiving options